Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2018

01-04-2018 | Bone and Soft Tissue Sarcomas

Analysis of the Infiltrative Features of Chordoma: The Relationship Between Micro-Skip Metastasis and Postoperative Outcomes

Authors: Toru Akiyama, MD, Koichi Ogura, MD, Tabu Gokita, MD, PhD, Satoshi Tsukushi, MD, PhD, Shintaro Iwata, MD, PhD, Tomoki Nakamura, MD, PhD, Akihiko Matsumine, MD, PhD, Tsukasa Yonemoto, MD, PhD, Yoshihiro Nishida, MD, PhD, Kazuo Saita, MD, PhD, Akira Kawai, MD, PhD, Seiichi Matsumoto, MD, PhD, Takehiko Yamaguchi, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2018

Login to get access

Abstract

Background

Chordomas are very rare primary malignant bone tumors that arise commonly from the sacrum (50–60%) and clivus (25–35%). Chordomas have a high rate of recurrence. The authors confirmed a unique histologic infiltration pattern of chordomas that resembles a skip-metastatic lesion in normal tissue around tumor, which they named “micro-skip metastasis.” This study aimed to examine the correlations between the clinicopathologic features of chordomas, including micro-skip metastasis, and the clinical outcomes, including overall survival, local recurrence-free survival, and distant metastasis-free survival.

Methods

The study analyzed histopathologic and clinical data from patients with sacral chordomas who underwent en bloc resection from July 1991 through July 2014. Cases with a minimum follow-up period shorter than 20 months after resection were excluded. Kaplan–Meier survival analyses with log-rank tests were performed for overall survival, metastasis-free survival, and recurrence-free survival.

Results

The study retrospectively reviewed 40 patients. The mean follow-up period was 98.2 months (range 22–297 months). The local recurrence rate was 41.3%. Micro-skip metastases, observed in 17 patients (42.5%), were associated with a significantly increased risk of local recurrence (p = 0.023) but not with overall survival or distant metastasis-free survival. Poorer overall survival was associated with histologic vascular invasion (p = 0.030) and a greater maximum tumor diameter (p = 0.050).

Conclusions

The presence of micro-skip metastasis was associated with a higher rate of local recurrence. The maximum tumor diameter and the presence of histologic vascular invasion were associated with poorer overall survival.
Literature
1.
Stacchiotti S, Casali PG, Lo Vullo S, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17:211–19.CrossRefPubMed
2.
Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13:e69–76.CrossRefPubMed
3.
Hanna SA, Aston WJ, Briggs TW, Cannon SR, Saifuddin A. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466:2217–23.CrossRefPubMedPubMedCentral
4.
Kayani B, Sewell MD, Tan KA, et al. Prognostic factors in the operative management of sacral chordomas. World Neurosurg. 2015;84:1354–61.CrossRefPubMed
5.
Yonemoto T, Tatezaki S, Takenouchi T, Ishii T, Satoh T, Moriya H. The surgical management of sacrococcygeal chordoma. Cancer. 1999;85:878–83.CrossRefPubMed
6.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.
7.
8.
Ruggieri P, Angelini A, Ussia G, Montalti M, Mercuri M. Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res. 2010;468:2939–47.CrossRefPubMedPubMedCentral
9.
Schwab JH, Healey JH, Rose P, Casas-Ganem J, Boland PJ. The surgical management of sacral chordomas. Spine. 2009;34:2700–04.CrossRefPubMed
10.
Hulen CA, Temple HT, Fox WP, Sama AA, Green BA, Eismont FJ. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. 2006;88:1532–39.CrossRefPubMed
11.
Dubory A, Missenard G, Lambert B, Court C. “En bloc’’ resection of sacral chordomas by combined anterior and posterior surgical approach: a monocentric retrospective review about 29 cases. Eur Spine J. 2014;23:1940–48.CrossRefPubMed
12.
Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsushita Y. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res. 2004;419:165–72.CrossRef
13.
Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI, Brennan MF. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg. 1999;134:190–94.CrossRefPubMed
14.
Pisters PW, Pollock RE. Staging and prognostic factors in soft tissue sarcoma. Semin Radiat Oncol. 1999;9:307–14.CrossRefPubMed
15.
Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424–34.CrossRefPubMedPubMedCentral
16.
Cao J, Hu JL, Chen C, et al. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study. J Clin Pathol. 2016;69:872–77.CrossRefPubMed
17.
Wang H, Li P, Zhang X, Xia Z, Lu Y, Huang H. Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T cell lymphoma, nasal type. Oncol Lett. 2016;12:825–36.CrossRefPubMedPubMedCentral
18.
Setälä LP, Kosma VM, Marin S, et al. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate, and lymphoplasmacytic infiltration. Br J Cancer. 1996;74:766–72.CrossRefPubMedPubMedCentral
19.
Slaton JW, Morgenstern N, Levy DA, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165:1138–42.CrossRefPubMed
20.
Yonemoto T, Tatezaki S, Ishii T, Iwata S, Takeuchi Y, Araki A. Histological vascular invasion by tumors is a risk factor for distant metastasis in malignant fibrous histiocytoma. Anticancer Res. 2005;25:1337–42.PubMed
21.
Carneiro A, Bendahl PO, Engellau J, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011;117:1279–87.CrossRefPubMed
22.
de Silva MV, McMahon AD, Paterson L, Reid R. Identification of poorly differentiated synovial sarcoma: a comparison of clinicopathological and cytogenetic features with those of typical synovial sarcoma. Histopathology. 2003;43:220–30.CrossRefPubMed
23.
Hsieh PC, Xu R, Sciubba DM, et al. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine. 2009;34:2233–39.CrossRefPubMed
24.
Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. Eur J Oncol. 2014;40:1412–20.CrossRef
25.
Ozaki T, Hillmann A, Winkelmann W. Surgical treatment of sacrococcygeal chordoma. J Surg Oncol. 1997;64:274–79.CrossRefPubMed
Metadata
Title
Analysis of the Infiltrative Features of Chordoma: The Relationship Between Micro-Skip Metastasis and Postoperative Outcomes
Authors
Toru Akiyama, MD
Koichi Ogura, MD
Tabu Gokita, MD, PhD
Satoshi Tsukushi, MD, PhD
Shintaro Iwata, MD, PhD
Tomoki Nakamura, MD, PhD
Akihiko Matsumine, MD, PhD
Tsukasa Yonemoto, MD, PhD
Yoshihiro Nishida, MD, PhD
Kazuo Saita, MD, PhD
Akira Kawai, MD, PhD
Seiichi Matsumoto, MD, PhD
Takehiko Yamaguchi, MD, PhD
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6268-6

Other articles of this Issue 4/2018

Annals of Surgical Oncology 4/2018 Go to the issue

Melanomas

Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors

Gastrointestinal Oncology

Robot-Assisted Technique for Total Gastrectomy and D2 Lymphadenectomy with Anomalous Vasculature

Head and Neck Oncology

Neoadjuvant Chemotherapy for Hypopharyngeal Squamous Cell Carcinoma and Personalized Medicine in Head and Neck Cancer

Pancreatic Tumors

Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?

Melanomas

Steps to Getting Your Manuscript Published in a High-Quality Medical Journal

Breast Oncology

Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer